Presbyterian College School of Pharmacy, Clinton, South Carolina.
Sr Care Pharm. 2021 Feb 1;36(2):83-92. doi: 10.4140/TCP.n.2021.83.
The purpose of this systematic review is to evaluate the available evidence for safety and efficacy of over-the-counter (OTC) sleep aids used for the treatment of insomnia in older people.
PubMed, EBSCO, and International Pharmaceutical Abstracts.
Five studies were included that involved humans 65 years of age and older being evaluated on OTC sleep aids in the outpatient setting.
Data extraction from each study included primary and secondary efficacy endpoints, such as differences in the mean total sleep time, sleep latency, sleep efficiency, and number of awakenings, along with safety endpoints, such as psychomotor ability, cognitive ability, and adverse effect profiles. Both subjective and objective measures of changes in sleep and adverse effects were included.
Diphenhydramine had a statistically significant increase in sedation and decrease in number of awakenings but was not shown to be any less or more safe than compared products. Despite lacking safety issues, valerian was found to have no effect on subjective or objective sleep outcomes. Overall, melatonin had the most evidence and was found to have a statistically significant positive impact on sleep measures without safety issues.
Diphenhydramine and melatonin appear to be efficacious in improving some sleep measures while causing minimal adverse effects. However, there are very few studies that examine the use of over-the-counter sleep aids in those 65 years of age and older with primary insomnia. Additional studies are needed in this population.
本系统评价旨在评估可用于治疗老年人失眠的非处方(OTC)助眠药物的安全性和有效性的证据。
检索了 PubMed、EBSCO 和国际药学文摘。
纳入了 5 项研究,这些研究均在门诊环境下评估了年龄在 65 岁及以上的人群使用 OTC 助眠药物的情况。
从每项研究中提取的数据包括主要和次要疗效终点,如平均总睡眠时间、睡眠潜伏期、睡眠效率和觉醒次数的差异,以及安全性终点,如精神运动能力、认知能力和不良事件谱。包括主观和客观的睡眠和不良反应变化的测量。
苯海拉明在镇静方面有统计学上的显著增加,而在觉醒次数方面则有所减少,但与比较产品相比,安全性没有降低或提高。尽管缬草根没有安全性问题,但对主观或客观的睡眠结果没有影响。总的来说,褪黑素的证据最多,且对睡眠测量有统计学上的显著积极影响,没有安全性问题。
苯海拉明和褪黑素似乎在改善一些睡眠测量方面有效,同时引起的不良反应最小。然而,几乎没有研究检查 65 岁及以上原发性失眠患者使用非处方助眠药物的情况。该人群需要更多的研究。